-+ 0.00%
-+ 0.00%
-+ 0.00%

TNF Pharmaceuticals And Renova Health Announce Initial Results From AI-Driven Study Of 30K Patients On GLP-1 Agonists, Highlighting Potential Of Isomyosamine To Improve Diagnosis, Preserve Muscle Mass, And Enhance Treatment For Inflammatory Conditions

Benzinga·05/08/2025 13:22:38
Listen to the news

Use of AI and machine learning accelerates identification of patient groups whose care can be improved

First study examines pro-inflammatory TNF-α levels in patients receiving GLP-1 agonists including Wegovy® or Ozempic®

Initial findings support opportunities to improve diagnosis and treatment and demonstrate isomyosamine's potential to impact quality of life in a general practice population

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy.

In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development.